Serum S100B indicates successful combination treatment with recombinant tissue plasminogen activator and MK-801 in a rat model of embolic stroke

Brain Research

Volumn 1154, Issue 1, 2007, Pages 194-199

  Tanaka, Yu ^a   Marumo, Toshiyuki ^a   Omura, Tomohiro ^a   Yoshida, Shigeru ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Brain edema; Brain infarction; Embolic stroke; MK 801; Rat; S100B; Tissue plasminogen activator

Indexed keywords

ACTIVACINE; ALTEPLASE; DIZOCILPINE; PROTEIN S100B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EDEMA; BRAIN INFARCTION SIZE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; EMBOLISM; EVALUATION; HISTOLOGY; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SPRAGUE DAWLEY RAT; STROKE;

ANIMALS; BRAIN EDEMA; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; LASER-DOPPLER FLOWMETRY; MALE; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; RATS; REGIONAL BLOOD FLOW; S100 PROTEINS; THROMBOEMBOLISM; TISSUE PLASMINOGEN ACTIVATOR;

RATTUS;

EID: 34249821886     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.03.085     Document Type: Article

References (31)

1. Büttner T., Weyers S., Postert T., Sprengelmeyer R., and Kuhn W. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke 28 (1997) 1961-1965
2. Chen LH., Liu LX., Yang YJ., Liu YS., and Cao MH. Neuroprotective effects of nimodipine and MK-801 on acute infectious brain edema induced by injection of pertussis bacilli to neocortex of rats. Chin. J. Traumatol. 6 (2003) 118-123
3. Chi OZ., Chang Q., and Weiss HR. Effects of topical N-methyl-d-aspartate on blood-brain barrier permeability in the cerebral cortex of normotensive and hypertensive rats. Neurol. Res. 19 (1997) 539-544
4. Diehl LA., Silveira PP., Leite MC., Crema LM., Portella AK., Billodre MN., Nunes E., Henriques TP., Fidelix-da-Silva LB., Heis MD., Goncalves CA., Quillfeldt JA., and Dalmaz C. Long lasting sex-specific effects upon behavior and S100b levels after maternal separation and exposure to a model of post-traumatic stress disorder in rats. Brain Res. 1144 (2007) 107-116
5. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., Rustenbeck HH., Breiter N., Jacob S., Knerlich F., Bohn M., Poser W., Ruther E., Kochen M., Gefeller O., Gleiter C., Wessel TC., De Ryck M., Itri L., Prange H., Cerami A., Brines M., and Siren AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8 (2002) 495-505
6. Elting JW., Sulter GA., Kaste M., Lees KR., Diener HC., Hommel M., Versavel M., Teelken AW., and De Keyser J. AMPA antagonist ZK200775 in patients with acute ischemic stroke 33 (2002) 2813-2818
7. Foerch C., du Mesnil de Rochemont R., Singer OC., Neumann-Haefelin T., Buchkremer M., Zanella FE., Steinmetz H., and Sitzer M. S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion. J. Neurol. Neurosurg. Psychiatry 74 (2003) 322-325
8. Foerch C., Otto B., Singer OC., Neumann-Haefelin T., Yan B., Berkefeld J., Steinmetz H., and Sitzer M. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 35 (2004) 2160-2164
9. Herrmann M., Vos P., Wunderlich MT., de Bruijn CHMM., and Lamers K.J.B. Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 31 (2000) 2670-2677
10. Gerriets T., Stolz E., Walberer M., Kaps M., Bachmann G., and Fisher M. Neuroprotective effects of MK-801 in different rat stroke models for permanent middle cerebral artery occlusion: adverse effects of hypothalamic damage and strategies for its avoidance. Stroke 34 (2003) 2234-2239
11. Gorgulu A., Kiris T., Unal F., Turkoglu U., Kucuk M., and Cobanoglu S. Protective effect of the N-methyl-d-aspartate receptor antagonists, MK-801 and CPP on cold-induced brain oedema. Acta Neurochir. 141 (1999) 93-98
12. Gorgulu A., Kins T., Cobanoglu S., Unal F., Izgi NI., Yanik B., and Kucuk M. Reduction of edema and infarction by Memantine and MK-801 after focal cerebral ischaemia and reperfusion in rat. Acta Neurochir. (Wien.) 142 (2000) 1287-1292
13. Kanner AA., Marchi N., Fazio V., Mayberg MR., Koltz MT., Siomin V., Stevens GHJ., Masaryk T., Ayumar B., Vogelbaum MA., Barnett GH., and Janigro D. Serum S100B: a noninvasive marker of blood-brain barrier function and brain lesion. Cancer 97 (2002) 2806-2813
14. Kapural M., Krizanac-Bengez Lj., Barnett G.., Perl J., Masaryk T., Apollo D., Rasmussen P., Mayberg MR., and Janigro D. Serum S100Beta as a possible marker of blood-brain barrier disruption. Brain Res. 940 (2002) 102-104
15. Kaste M. Thrombolysis in ischaemic stroke-Present and future: role of combined therapy. Cerebrovasc. Dis. 11 Suppl 1 (2001) 55-59
16. Kaur J., Zhao Z., Klein GM., Lo EH., and Buchan AM. The neurotoxicity of tissue plasminogen activator?. J. Cereb. Blood Flow Metab. 24 (2004) 945-963
17. Kent TA., Soukup VM., and Fabian RH. Heterogeneity affecting outcome from acute stroke therapy: making reperfusion worse. Stroke 32 (2001) 2318-2327
18. Kilic E., Kilic U., Bahr M., and Hermann D.M. Tissue plasminogen activator-induced ischemic injury is reversed by NMDA antagonist MK-801 in vivo. Neurodegener. Dis. 2 (2005) 49-55
19. Nicole O., Docagne F., Ali C., Margaill I., Carmeliet P., MacKenzie E.T., Vivien D., and Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med. 7 (2001) 59-64
20. Persson L., Hardemark H.G., Gustafsson J., Rundstrom G., Mendel-Hartvig I., Esscher T., and Pahlman S. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 18 (1987) 911-918
21. Rogalewski A., Schneider A., Ringelstein E.B., and Schabitz W.R. Toward a multimodal neuroprotective treatment of stroke. Stroke 37 (2006) 1129-1136
22. Scaccianoce S., Del Bianco P., Pannitteri G., and Passarelli F. Relationship between stress and circulating levels of S100B protein. Brain Res. 1004 (2004) 208-211
23. Rosenberg G.A. Ischemic brain edema. Prog. Cardiovasc. Dis. 42 (1996) 209-216
24. Shirasaki Y., Edo N., and Sato T. Serum S100B protein as a biomarker for the assessment of neuroprotectants. Brain Res. 1021 (2004) 159-166
25. Shapira Y., Yadid G., Cotev S., Niska A., and Shohami E. Protective effect of MK801 in experimental brain injury. J. Neurotrauma 7 (1990) 131-139
26. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30 (1999) 2752-2758
27. Tanaka Y., Koizumi C., Marumo T., Omura T., and Yoshida S. Serum S100B indicates brain edema formation and predicts long-term neurological outcomes in rat transient middle cerebral artery occlusion model. Brain Res. 1137 (2007) 140-145
28. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333 (1995) 1581-1587
29. Wunderlich M.T., Ebert A.D., Kratz T., Goertler M., Jost S., and Herrmann M. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 30 (1999) 1190-1195
30. Zhang R.L., Chopp M., Zhang Z.G., Jiang Q., and Ewing J.R. A rat model of focal embolic cerebral ischemia. Brain Res. 766 (1997) 83-92
31. Zivin J.A., and Mazzarella V. Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch. Neurol. 48 (1991) 1235-1238